Drug Profile
SBT 102
Alternative Names: SB-102Latest Information Update: 28 Apr 2023
Price :
$50
*
At a glance
- Originator Singh Biotechnology
- Class Antineoplastics; Single-domain antibodies
- Mechanism of Action KRAS protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Apr 2023 No recent reports of development identified for research development in Cancer in USA
- 29 Mar 2019 Early research is ongoing in USA
- 28 Aug 2018 No recent reports of development identified for research development in Cancer in USA